Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,549
  • Shares Outstanding, K 7,372
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,740 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.77

Options Overview Details

View History
  • Implied Volatility 38.04% (+1.16%)
  • Historical Volatility 64.31%
  • IV Percentile 4%
  • IV Rank 0.42%
  • IV High 941.28% on 04/14/25
  • IV Low 34.18% on 03/31/26
  • Expected Move (DTE 14) 0.26 (3.45%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 52
  • Volume Avg (30-Day) 267
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 3,587
  • Open Int (30-Day) 2,415
  • Expected Range 7.15 to 7.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.98
  • Number of Estimates 1
  • High Estimate $-0.98
  • Low Estimate $-0.98
  • Prior Year $-2.27
  • Growth Rate Est. (year over year) +56.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.08 +21.71%
on 03/27/26
7.55 -1.99%
on 04/02/26
+0.33 (+4.67%)
since 03/02/26
3-Month
6.03 +22.72%
on 02/06/26
7.55 -1.99%
on 04/02/26
+1.11 (+17.65%)
since 01/02/26
52-Week
3.53 +109.43%
on 10/07/25
7.55 -1.99%
on 04/02/26
+2.80 (+60.87%)
since 04/02/25

Most Recent Stories

More News
Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KZR : 7.40 (unch)
EQH : 37.79 (+0.45%)
NSA : 39.12 (+1.58%)
CTRA : 34.56 (+1.89%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)

NEW YORK , March 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

KZR : 7.40 (unch)
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

KZR : 7.40 (unch)
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

KZR : 7.40 (unch)
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has...

AUPH : 15.61 (+0.90%)
KZR : 7.40 (unch)
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors

KZR : 7.40 (unch)
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

Kezar Life Sciences, Inc . (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that...

KZR : 7.40 (unch)
Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results...

KZR : 7.40 (unch)
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two...

KZR : 7.40 (unch)
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Kezar Life Sciences, Inc . (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today...

KZR : 7.40 (unch)

Business Summary

Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South...

See More

Key Turning Points

3rd Resistance Point 7.72
2nd Resistance Point 7.63
1st Resistance Point 7.52
Last Price 7.40
1st Support Level 7.32
2nd Support Level 7.23
3rd Support Level 7.12

See More

52-Week High 7.55
Last Price 7.40
Fibonacci 61.8% 6.02
Fibonacci 50% 5.54
Fibonacci 38.2% 5.07
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.